



Exome sequencing identifies germline variants in DIS3 in familial
multiple myeloma
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To the Editor:
Multiple myeloma (MM) is the third most common hemato-
logical malignancy, after Non-Hodgkin Lymphoma and Leu-
kemia. MM is generally preceded by Monoclonal Gammopathy
of Undetermined Significance (MGUS) [1], and epidemiolo-
gical studies have identified older age, male gender, family
history, and MGUS as risk factors for developing MM [2].
The somatic mutational landscape of sporadic MM has
been increasingly investigated, aiming to identify recurrent
genetic events involved in myelomagenesis. Whole exome
and whole genome sequencing studies have shown that MM
is a genetically heterogeneous disease that evolves through
accumulation of both clonal and subclonal driver mutations
[3] and identified recurrently somatically mutated genes,
including KRAS, NRAS, FAM46C, TP53, DIS3, BRAF,
TRAF3, CYLD, RB1 and PRDM1 [3–5].
Despite the fact that family-based studies have pro-
vided data consistent with an inherited genetic suscept-
ibility to MM compatible with Mendelian transmission
[6], the molecular basis of inherited MM predisposition is
only partly understood. Genome-Wide Association
(GWAS) studies have identified and validated 23 loci
significantly associated with an increased risk of devel-
oping MM that explain ~16% of heritability [7] and only a
subset of familial cases are thought to have a polygenic
background [8]. Recent studies have identified rare
germline variants predisposing to MM in KDM1A [9],
ARID1A and USP45 [10], and the implementation of next-
generation sequencing technology will allow the char-
acterization of more such rare variants.
In this study, we sought to explore the involvement of
rare germline genetic variants in susceptibility to MM.
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Within our discovery cohort of peripheral blood samples
(see Supplementary Methods) from 66 individuals from 23
unrelated families analyzed by WES, DIS3 (NM_014953)
was the only gene in which putative loss-of-function variants
were observed in at least two families. An additional cohort
of 937 individuals (148 MM, 139 MGUS, 642 unaffected
relatives and eight individuals with another hematological
condition) from 154 unrelated families (including the indi-
viduals in the discovery cohort) were screened for germline
variants in DIS3 using targeted sequencing (Supplementary
Table S1). In total, we detected DIS3 germline putative loss-
of-function variants in four unrelated families. The DIS3
genotypes for the identified variants were concordant
between WES and targeted sequencing (where available)
and independently confirmed by Sanger sequencing on
DNA extracted from uncultured whole blood. The variant
allele frequencies (VAF) were close to 50%, as expected of a
germline variant (Supplementary figure S1).
The DIS3 gene, located in 13q22.1, encodes for the cata-
lytic subunit of the human exosome complex, and is recur-
rently somatically mutated in MM patients [4, 5, 11, 12].
The somatic variants are predominantly missense variants
localized in the RNB domain mainly abolishing the
exoribonucleolytic activity [4, 13], and are often accom-
panied by LOH or biallelic inactivation due to 13q14
deletion, implying a tumor suppressor role for DIS3 in MM
[5, 12, 13].
The first DIS3 variant, observed in 2 affected siblings
(1 MGUS and 1 MM case) from family B (Fig. 1a), was
located in the splice donor site of exon 13 (c.1755+1G>T;
chr13: 73,345,041; GRCh37/hg19, rs769194741) (Supple-
mentary Figure S1a). It is predicted to abolish the splice donor
site and cause skipping of exon 13, introducing a premature
termination codon (p.Arg557Argfs*3) and result in a trun-
cated DIS3 protein that lacks part of the exonucleolytic active
RNB and S1 domains (Fig. 1b, c). The presence of this var-
iant in two siblings, implying Mendelian segregation, is
consistent with a germline, rather than somatic, origin. We
investigated whether a DIS3 transcript from the variant allele
is generated but is subsequently eliminated by Nonsense
Mediated Decay (NMD) by incubating Lymphoblastoid Cell
Lines (LCLs) derived from the two c.1755+1G>T allele
carriers with and without puromycin, which suppresses NMD.
The mRNA transcript corresponding to the variant allele was
clearly present in LCLs treated with puromycin in both car-
riers, whereas not detectable in untreated LCLs (Fig. 2a),
consistent with the variant allele being transcribed but sub-
sequently degraded via the NMD pathway. In line with this
observation, analysis of DIS3 mRNA expression by qRT-
PCR showed an average 50% reduced expression in the
c.1755+1G>T carriers (range 40.7−61.4%) as compared to
non-carriers (Fig. 2b). A second splicing variant (c.1883
+1G>C; chr13: 73,342,922; GRCh37/hg19) located in the
splice donor site of exon 14 within the RNB domain was
identified in a MM case from family D (Fig. 1a, b, Supple-
mentary figure S1c). However, the individual’s mother
(Q59), affected with amyloidosis, did not carry the variant,
implying that MM in the allele carriers’ maternal uncles is
unlikely to be explained by this DIS3 variant. Whether the
mRNA transcript encoded by this germline variant under-
goes NMD could not be explored due to lack of appropriate
material (LCLs, RNA).
A third DIS3 variant disrupting the wild-type termination
codon (stop-loss) (c.2875T>C; p.*959Gln; chr13:73,333,935;
GRCh37/hg19, rs141067458) (Fig. 1b, Supplementary Fig-
ure S1b) was identified in two unrelated families (A and C,
Fig. 1a). This variant is expected to result in a putative read-
through variant and a DIS3 protein with an additional 13 amino
acids in the C-terminus (p.*959Glnext*14). It was detected in 3
out of 4 affected siblings (2 MGUS (M63, O53) and 1 MM
case (O29)), as well as 5 unaffected relatives (N14, N13, L41,
M33 M50) from family A. The Mendelian segregation of this
variant in this pedigree is also consistent with germline origin.
An additional MM case from family C carried the variant, while
we were unable to assess the other MM-afflicted family
member (Fig. 1a). As expected of a stop-loss variant, NMDwas
not observed (data not shown), and gene expression analysis
showed no effect on DIS3 mRNA levels (Fig. 2b). However,
western blot analysis demonstrated that DIS3 protein levels
were markedly lower (~50%) in the p.*959Glnext*14 carrier
(O53, family A) compared to non-carriers (Fig. 2b, c).
Next, we sought to determine if rare, putative deleterious
variants in DIS3 were more frequent in an independent series
of MM cases compared to unaffected individuals. We per-
formed mutation burden tests between 781 MM cases and
3534 controls from the MMRF CoMMpass Study with WES
data available. After testing for systemic bias in this dataset
(see Supplementary Methods, Supplementary Figure S2), we
undertook a burden test for association between functional
DIS3 variants and MM. DIS3 putative functional variants
(truncating and likely deleterious missense variants, see Sup-
plementary Methods) were more frequent among MM
patients (30/781) than controls (72/3534) (OR= 1.92 95%
CI:1.25–2.96, p= 0.001). Although the p.*959Glnext*14
stop-loss variant was recurrently found in 10/781 MM cases
and 15/3534 controls (OR= 3.07 95%CI:1.38 to 6.87, p=
0.0007), it did not entirely explain the excess of DIS3 variants
among cases as there is evidence for association with other
putative functional variants (Supplementary Figure S3a). We
additionally genotyped the p.*959Glnext*14 stop-loss variant
in an independent series of sporadic MM cases and controls
from the IMMEnSE Consortium. While this variant was very
rare in this series (8/3020 MM cases relative to 3/1786 con-
trols), there was a consistent but non-significant association
between this variant and MM (OR= 3.15 95% CI: 0.74–
13.43 p= 0.122).
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To explore the functional consequence of germ-
line DIS3 variants, we compared MM tumor transcriptomes
from patients harboring germline (n= 21) and somatic (n=
96) DIS3 putative functional variants to non-carriers (n=
655). Differential expression analyses showed an enrichment
of pathways associated with global ncRNA processing and
translational termination in germline DIS3 carriers including
ncRNA processing, ncRNA metabolic process, translational
termination, and RNA metabolism. Among somatic DIS3
carriers, significantly enriched pathways include interferon
alpha/beta signalling, mRNA splicing, mRNA processing and
transcription (Supplementary Figure S3b, Supplementary
tables S3 and S4a–d). These findings are consistent with the
proposed DIS3 role in regulating mRNA processing [14] and
Fig. 1 DIS3 variants in MM cases. a Pedigrees from families carrying
a germline DIS3 variant. Available samples for screening are marked
with a “+” symbol. Families A and C carry the p.*959Glnext*14
(c.2875T>C) stop-loss variant. Family B carries the c.1755+1G>T
splicing variant and family D carries the c.1883+1G>C splicing var-
iant. The genotype of all screened individuals is shown on each ped-
igree. WT: wild type. b, c Schematic representation of identified
germline and somatic variants in the distinct DIS3 protein domains. b
Germline variants were identified through WES and targeted
resequencing in families with reoccurrence of MM/MGUS as well as
in a collection of sporadic MM cases (MMRF CoMMpass Study). The
DIS3 variants discussed in the present study are depicted with a star on
the upper part of the figure. c Somatic DIS3 variants were identified in
sporadic MM cases from the MMRF CoMMpass Study. We observe
that in contrast to the clustering of somatic DIS3 missense variants in
the RNB and PIN domains, germline variants are scattered throughout
the gene and consist of splicing, stop-loss and missense variants
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more specifically mRNA decay, gene expression and small
RNA processing [15]. We also observed that, several long-
intergenic non-protein coding RNAs, non-coding and anti-
sense RNAs were significantly enriched among DIS3 carriers
(Supplementary table S5a, b) supporting previous studies that
demonstrate an accumulation of transcripts from non-protein
coding regions, snoRNA precursors and certain lncRNAs in
DIS3 mutant cells, along a general deregulation of mRNA
levels probably due to the sequestration of transcriptional
factors from the accumulated nuclear RNAs [16].
To our knowledge, this is the first observation of germline
DIS3 likely deleterious variants in familial MM and our
results suggest that the involvement of DIS3 in MM etiology
may extend beyond somatic alterations to germline suscept-
ibility. We reported rare germline DIS3 variants in ~2.6% of
our cohort of families with multiple cases of MM and MGUS
(4/154). The germline variants described here are predicted to
have loss-of-function impact on DIS3. Consistent with this,
the 1755+1G>T (rs769194741) splicing variant induces
NMD and results in reduced DIS3 mRNA expression, sup-
porting the proposal that DIS3 is acting as a tumor suppressor
gene in MM [13]. Moreover, the c.2875T>C (rs141067458)
stop-loss variant (p.*959Glnext*14) results in reduced DIS3
protein expression suggesting that the mutant allele is trans-
lated but degraded shortly after. Notably, in contrast to the
clustering of somatic DIS3 mutations in the PIN and RNB
domains, germline variants identified both in familial and
sporadic MM cases are scattered throughout the gene (Fig. 1b,
c). Despite the fact that these variants do not segregate per-
fectly with MM in the identified families and the rarity of
DIS3 germline likely deleterious variants limits our statistical
power, the subsequent mutation burden and transcriptome
Fig. 2 DIS3 c.1755+1G>T splicing variant results in nonsense-
mediated mRNA decay (NMD) and affects mRNA expression, while
the c.2875C>T (p.*959Glnext*14) stop-loss variant affects protein
levels. a LCLs from patients E18 and E28 (not shown) carrying the
c.1755+1G>T splicing variant were cultured with and without pur-
omycin. The chromatogram from treated cells (with puromycin)
showed a mixture of the wild-type and mutant transcript lacking exon
13, which was not detected in the non-treated cells (without pur-
omycin). Thus, the mutant transcript is degraded by NMD. b Box plot
representing the relative DIS3 mRNA expression in c.1775+1G>A
(n=2) and p.*959Glnext*14 (n= 1) carriers compared to non-carriers
(n= 4). All reactions were performed in triplicates. c Western blot
with an anti-DIS3 antibody was performed in LCLs from one p.
*959Glnext*14 carrier and two wild-type individuals (anti-GAPDH
antibody as internal control). The relative DIS3 expression in the p.
*959Glnext*14 carrier was reduced by 50% compared to non-carriers,
suggesting that the mutant allele is translated but degraded shortly after
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analyses provided supportive data towards DIS3 acting as an
“intermediate-risk” MM susceptibility gene.
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